Evidence map›Paper›PMID 22290066›Full record

ArticleLeukemia2012

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.

A Spyridonidis, M Labopin, C Schmid, L Volin, I Yakoub-Agha, M Stadler, N Milpied, G Socie, P Browne, S Lenhoff and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Trial
  5. Trial
  6. Trial
  7. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Trial
  12. Trial
  13. Article
  14. Observational
  15. [Uterine and ovarian relapse of acute lymphoblastic leukemia after transplantation: A case report].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

A SpyridonidisDivision of Hematology , BMT Unit, University of Patras, Patras, Greece. spyridonidis@upatras.gr
M Labopin
C Schmid
L Volin
I Yakoub-Agha
M Stadler
N Milpied
G Socie
P Browne
S Lenhoff
M A Sanz
M Aljurf
M Mohty
V Rocha
Immunotherapy Subcommittee of Acute Leukemia Working Party

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To describe outcomes, treatment and prognostic factors that influence survival of adult patients with acute lymphoblastic leukemia (ALL), who relapsed after allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed 465 ALL adult patients from European Group for Blood and Marrow Transplantation (EBMT) centers who relapsed after a first HCT performed in complete remission (CR1 65%, CR2/3 35%). Salvage treatments were: supportive care (13%), cytoreductive therapy (43%), donor lymphocyte infusion without or with prior chemotherapy (23%) and second HCT (20%). Median time from HCT to relapse was 6.9 months, median follow-up was 46 months and median survival after relapse was 5.5 months. Estimated 1-, 2- and 5-year post-relapse survival was 30 ± 2%, 16 ± 2% and 8 ± 1%, respectively. In a multivariate analysis, adverse factors for survival were: late CR (CR2/3) at transplant (P<0.012), early relapse after transplant (<6.9 months, P <0.0001) and peripheral blast percent at relapse (P <0.0001). On the basis of multivariate model for survival, three groups of patients were identified with estimated 2 year survival of 6 ± 2, 17 ± 3 and 30 ± 7%. Outcome of ALL patients relapsing after HCT is dismal and there is a need for new therapies. Our study provides the standard expectations in ALL relapse and may help in the decision of post-relapse therapy.

Indexed as

Salvage TherapyAdolescentAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionRetrospective StudiesRisk FactorsSurvival RateTransplantation, Homologous

Identifiers

PMID22290066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.